InMode Ltd. (NASDAQ:INMD) Receives $16.60 Average Target Price from Analysts

Shares of InMode Ltd. (NASDAQ:INMD) have received an average rating of “Hold” from the ten ratings firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $16.60.

Several research firms have recently issued reports on INMD. Zacks Research raised shares of InMode from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. Canaccord Genuity Group set a $15.00 price target on InMode and gave the stock a “hold” rating in a research report on Wednesday, December 17th. Wall Street Zen cut InMode from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of InMode in a research note on Friday, October 10th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of InMode in a research note on Wednesday, October 8th.

Institutional Trading of InMode

Several institutional investors have recently modified their holdings of INMD. Parallel Advisors LLC raised its position in shares of InMode by 63.1% during the 2nd quarter. Parallel Advisors LLC now owns 1,973 shares of the healthcare company’s stock worth $28,000 after purchasing an additional 763 shares during the last quarter. American Century Companies Inc. increased its stake in InMode by 6.1% during the 1st quarter. American Century Companies Inc. now owns 18,994 shares of the healthcare company’s stock worth $337,000 after buying an additional 1,087 shares in the last quarter. Aviva PLC raised its holdings in shares of InMode by 3.9% during the second quarter. Aviva PLC now owns 33,264 shares of the healthcare company’s stock valued at $480,000 after acquiring an additional 1,263 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of InMode by 93.7% during the third quarter. Blue Trust Inc. now owns 2,861 shares of the healthcare company’s stock valued at $43,000 after acquiring an additional 1,384 shares during the last quarter. Finally, Advisory Services Network LLC purchased a new position in shares of InMode in the third quarter valued at approximately $37,000. Institutional investors and hedge funds own 68.04% of the company’s stock.

InMode Stock Performance

Shares of NASDAQ INMD opened at $15.19 on Friday. The company has a market capitalization of $960.16 million, a PE ratio of 7.03 and a beta of 2.13. The company’s fifty day moving average price is $14.44 and its 200 day moving average price is $14.63. InMode has a 1 year low of $13.14 and a 1 year high of $19.78.

InMode Company Profile

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.